Candel Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 14, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.”
Candel Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Candel Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Candel Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2025.
“On March 12, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2025.”
Candel Therapeutics, Inc. entered into Underwriting Agreement with Citigroup Global Markets Inc., Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated valued at approximately $93.5 million (effective 2026-02-19).
“On February 19, 2026, Candel Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc., Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 18,348,624 shares (the “Firm Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), at a price to the public of $5.45 per share (the “Offering”).”
Candel Therapeutics, Inc. entered into Purchase Agreement with funds managed by RTW Investments, LP valued at $100 million (effective 2026-02-19).
“On February 19, 2026, Candel Therapeutics, Inc. (the “Company”) announced its entry into a purchase and sale agreement (the “Purchase Agreement”) with funds managed by RTW Investments, LP (the “Purchaser”). Under the terms of the Purchase Agreement, the Purchaser has agreed to pay the Company $100 million”
Candel Therapeutics, Inc. issued 3.0% of the applicable draw of warrant to the Lenders (Trinity Capital Inc., as administrative agent and collateral agent).
“The issuance of the Lender Warrants are exempt from the requirements of the Securities Act of 1933, as amended, pursuant to an exemption provided by Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder as transactions by an issuer not involving a public offering.”
Candel Therapeutics, Inc. incurred term loan of aggregate principal amount of up to $130.0 million with lenders party thereto and Trinity Capital Inc., as administrative agent and collateral agent at the greater of (a) the sum of (i) The Wall Street Journal Prime Rate and (ii) 3. maturing October 1, 2030.
“(the “Agent”). Under the LSA, the Lenders agreed to extend debt capital to the Company, in the form of a term loan, in tranches totaling an aggregate principal amount of up to $130.0 million as follows: (a) at closing, the aggregate principal amount of $50.0 million (the “First Tranche”), (b) until May 30, 2027, subject to the achievement of certain regulatory,”
Charles Schoch was appointed as Chief Financial Officer at Candel Therapeutics, Inc..
“On June 20, 2025, the board of directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) unanimously appointed Charles Schoch as the Company’s Chief Financial Officer, effective June 20, 2025”
Maha Radhakrishnan, M.D. was appointed as Director at Candel Therapeutics, Inc..
“On June 4, 2025, the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) to ten (10) directors and unanimously appointed Maha Radhakrishnan, M.D., to fill the newly created vacancy on the Board, effective June 4, 2025.”
Candel Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.
“On May 14, 2024, Candel Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
Candel Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $11.1 million.
“Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2023.”
Charles Schoch was appointed as interim Chief Financial Officer at Candel Therapeutics, Inc..
“unanimously appointed Charles Schoch as the Company’s interim Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024.”
Jason A. Amello resigned as Chief Financial Officer at Candel Therapeutics, Inc..
“Jason A. Amello resigned from his position as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, effective January 12, 2024, to pursue another opportunity.”
Charles Schoch was appointed as Interim Chief Financial Officer at Candel Therapeutics, Inc..
“Effective upon Mr. Amello’s cessation of service as Chief Financial Officer, the Company intends to appoint Charles Schoch, the Company’s current Vice President of Finance and Corporate Controller, as the Company’s Interim Chief Financial Officer, principal financial and principal accounting officer while the Company engages in a search for a permanent replacement for Mr. Amello.”
Jason A. Amello resigned as Chief Financial Officer at Candel Therapeutics, Inc..
“On December 11, 2023, Jason A. Amello notified Candel Therapeutics, Inc. (the “Company”) of his decision to resign from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024, to pursue another opportunity.”
Candel Therapeutics, Inc. announced a restructuring with charges of approximately $0.7 million affecting the Company (approximately 50%).
“On November 26, 2023, the Board of Directors (the “Board”) of Candel Therapeutics, Inc (the "Company") approved a strategic restructuring to focus on continuation and expansion of development of CAN-3110 as well as the enLIGHTEN TM Discovery Platform, and reducing the Company’s workforce by approximately 50%, as well as reducing expenses associated with enabling commercial readiness of CAN-2409, while maintaining and prioritizing key clinical readouts in 2024 (the “Restructuring Plan”). In connection with the Restructuring Plan, the Company estimates that it will incur a one-time restructuring charge of approximately $0.7 million in the fourth quarter of 2023 related to severance and healthcare and related benefits costs.”
Candel Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“November 15, 2023, Candel Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.01 per share (the “Common Stock”), had been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The Notice has no effect at this time on the Common Stock, w”
Candel Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 9, 2023, Candel Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2023.”
Candel Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $9.6 million.
“On August 10, 2023, Candel Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
Candel Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-28 meeting.
“The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, recommended for ratification in Proposal 2 at the Annual Meeting. The votes cast at the Annual Meeting were as follows: For Against Abstain 15,388,012 82,122 1,081”
Candel Therapeutics, Inc. shareholders approved Election of three Class II directors at the 2023-06-28 meeting.
“The Company’s stockholders elected each of the Class II director nominees, Edward J. Benz Jr., M.D., Paul B. Manning, and Paul Peter Tak, M.D., Ph.D., FMedSci, recommended for election at the Annual Meeting in Proposal 1. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes Edward J. Benz Jr., M.D. 10,762,707 205,866 - 4,502,642 Paul B. Manning 10,903,287 65,286 - 4,502,642 Paul Peter Tak, M.D., Ph.D., FMedSci 10,930,887 37,686 - 4,502,642”
Nicoletta Loggia was appointed as Class III Director at Candel Therapeutics, Inc..
“unanimously appointed Nicoletta Loggia, Ph.D., R.Ph., to fill the newly created vacancy on the Board, effective June 7, 2023.”
Candel Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $8.8 million.
“Net loss for the first quarter of 2023 was $8.8 million compared to a net loss of $0.9 million for the first quarter of 2022, and included net other income of $0.8 million and $8.1 million, respectively, primarily related to the change in the fair value of the Company’s warrant liability.”
Candel Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.
“On March 30, 2023, Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2022.”
Candel Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $31,000, net income $8.7 million.
“Research and Development Service Revenue, related party: Research and Development Service Revenue, related party, for the third quarters ended September 30, 2022 and 2021 was $31,000. Research and Development Expenses: Research and development expenses were $5.4 million for the quarter ended September 30, 2022 compared to $5.3 million for the comparable”
Garrett Nichols was appointed as Chief Medical Officer at Candel Therapeutics, Inc..
“appointed Garrett Nichols. M.D., M.S., as the Company’s Chief Medical Officer, effective September 12, 2022”
Jason Amello was appointed as Chief Financial Officer at Candel Therapeutics, Inc..
“Jason Amello as the Company’s Chief Financial Officer, effective September 21, 2022.”
John Canepa resigned as Chief Financial Officer at Candel Therapeutics, Inc..
“On September 6, 2022, Candel Therapeutics, Inc. (the “Company”) accepted the resignation of John Canepa as the Company’s Chief Financial Officer, effective September 21, 2022.”
Joseph Papa was appointed as Director at Candel Therapeutics, Inc..
“The Board unanimously appointed Renee Gaeta, Dr. Gary Nabel and Joseph Papa, effective August 8, 2022, to fill the newly created vacancies on the Board resulting from the resignations of Dr. Gandhi, Dr. Meirav and Dr. Smith.”
Dr. Gary Nabel was appointed as Director at Candel Therapeutics, Inc..
“The Board unanimously appointed Renee Gaeta, Dr. Gary Nabel and Joseph Papa, effective August 8, 2022, to fill the newly created vacancies on the Board resulting from the resignations of Dr. Gandhi, Dr. Meirav and Dr. Smith.”
Renee Gaeta was appointed as Director at Candel Therapeutics, Inc..
“The Board unanimously appointed Renee Gaeta, Dr. Gary Nabel and Joseph Papa, effective August 8, 2022, to fill the newly created vacancies on the Board resulting from the resignations of Dr. Gandhi, Dr. Meirav and Dr. Smith.”
Alan E. Smith resigned as Director at Candel Therapeutics, Inc..
“On July 26, 2022, Shaan Gandhi, Udi Meirav, and Alan E. Smith resigned as members of the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) effective August 8, 2022.”
Udi Meirav resigned as Director at Candel Therapeutics, Inc..
“On July 26, 2022, Shaan Gandhi, Udi Meirav, and Alan E. Smith resigned as members of the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) effective August 8, 2022.”
Shaan Gandhi resigned as Director at Candel Therapeutics, Inc..
“On July 26, 2022, Shaan Gandhi, Udi Meirav, and Alan E. Smith resigned as members of the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) effective August 8, 2022.”
Laura Aguilar was removed as officer at Candel Therapeutics, Inc..
“On January 28, 2022, Candel Therapeutics, Inc. (the “Company”) removed Estuardo Aguilar-Cordova and Laura Aguilar from their roles as officers of the Company, without cause under their respective employment agreements with the Company, with such termination expected to be effective on February 7, 2022.”
Estuardo Aguilar-Cordova was removed as officer at Candel Therapeutics, Inc..
“On January 28, 2022, Candel Therapeutics, Inc. (the “Company”) removed Estuardo Aguilar-Cordova and Laura Aguilar from their roles as officers of the Company, without cause under their respective employment agreements with the Company, with such termination expected to be effective on February 7, 2022.”
Diem Nguyen was appointed as Director at Candel Therapeutics, Inc..
“On July 12, 2021, the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) unanimously appointed Diem Nguyen, Ph.D. to fill a newly created vacancy on the Board”
Carrie Cox resigned as Director at Candel Therapeutics, Inc..
“resulting from the resignation of Carrie Cox from the Board”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.